CAREERS
If you are interested in working for Healthcare Economics LLC, please send a Curriculum Vitae and specific career interests to: info@healthcare-economics-llc.com. We look forward to hearing from you.
NEWS and EVENTS
The Patent Cliff Threatens Billions of Global Pharmaceutical Sales
The patent cliff is real. During 2010 -2017 and during 2019-2024 approximately USD $150B and $198B respectively either have been and or are at risk of losing patent protection. Worldwide prescription drug sales are expected to grow at a CAGR of 6.9 percent to $842 billion during the 2019-2024 time period. This is triple the CAGR seen for 2010-2019 and is driven by an increase in FDA approvals for novel drugs and growth in the oncology therapies and orphan drugs markets.
Healthcare Economics (HCE) has developed extensive contacts with manufacturers, technology clusters, and academia to supply the needed link into each sector with its proven experience and globally developed extensive network. Therefore, the opportunity is immense for HCE to partner with firms to supplement their pipelines to ensure future success.
USA Biosimilar Approval and Launch Dates
| Originator | Trade Name | Drug Name | Innovator & Drug Name Approval & Launch Dates | Innovator & Drug Name Approval & Launch Dates | Innovator & Drug Name Approval & Launch Dates | Innovator & Drug Name Approval & Launch Dates | Innovator & Drug Name Approval & Launch Dates |
|---|---|---|---|---|---|---|---|
| Roche | Herceptin | Trastuzumab | Mylan Ogivri Dec 2017(A) Nov 2019(L) |
Teva Herzuma Dec 2018(A) Mar 2019(L) |
Merck Ontruzant Jan 2019(A) Apr 2020(L) |
Pfizer Trazimera Mar 2019(A) Feb 2020(L) |
Amgen Kanjinti Jun 2019(A) Jul 2019(L) |
| Roche | Rituxan | Rituximab | Teva Truxima Nov 2018(A) Nov 2019(L) |
Pfizer Ruxience Jul 2019(A) Jan 2020(L) |
Amgen Riabni Dec 2020(A) Jan 2021(L) |
Pfizer Trazimera Mar 2019(A) Feb 2020(L) |
Amgen Kanjinti Jun 2019(A) Jul 2019(L) |
| Roche | Avastin | Bevacizumab | Amgen Mvasi Sept 2017(A) Jul 2019(L) |
Pfizer Zirabev Jun 2019(A) Jan 2020(L) |
|||
| J & J | Remicade | Infliximab | Pfizer Ixifi Dec 2014(A) |
Pfizer Inflectra Apr 2016(A) Nov 2016(L) |
Merck Renflexis Apr 2017(A) Jul 2018(L) |
Amgen Avsola Dec 2019(A) Jul 2020(L) |
|
| AbbVie | Humira | Adalimumab Launch Delayed Until 2023 |
Amgen Amjevita Sept 2016(A) |
Boehringer Ingelheim Cyltezo Aug 2017(A) |
Merck Hyrimoz Oct 2018 |
Merck Hadlima Jul 2019 |
|
| Amgen | Enbrel | Etanercept On-going Litigation |
Sandoz Erelzi Aug 2016 |
Samsung Eticovo Apr 2019 |
|||
| Amgen | Epogen | Epoetin Alfa | Pfizer Retacrit May 2018(A) Nov 2018(L) |
||||
| Amgen | Neupogen | Filgrastim | Sandoz Zarxio Mar 2015(A) Sept 2015(L) |
Pfizer Nivestym Jul 2018(A) Oct 2018(L) |
|||
| Amgen | Neulasta | Pegfilgrastim | Mylan Fulphila Jun 2018(A) Jul 2018(L) |
Coherus Udenyca Nov 2018(A) Jan 2019(L) |
Sandoz Ziextenzo Nov 2019(A) Dec 2019(L) |
Pfizer Nyvepria June 2020(A) Dec 2020(L) |